IP Verse

Methods And Compositions For Treating Complement-Associated Disorders - EP2894165

The patent EP2894165 was granted to Alexion Pharmaceuticals on Jan 4, 2023. The application was originally filed on Nov 10, 2009 under application number EP15152757A. The patent is currently recorded with a legal status of "Revoked".

EP2894165

ALEXION PHARMACEUTICALS
Application Number
EP15152757A
Filing Date
Nov 10, 2009
Status
Revoked
Aug 15, 2025
Publication Date
Jan 4, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SAMSUNG BIOEPISOct 4, 2023SIMMONS & SIMMONS MUNICHADMISSIBLE
AMGEN TECHNOLOGY IRELAND UNLIMITEDMay 17, 2023DORRIESADMISSIBLE
AMGEN TECHNOLOGY IRELAND UNLIMITEDMay 17, 2023DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMANADMISSIBLE

Patent Citations (112) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0430539
DESCRIPTIONEP0463151
DESCRIPTIONEP0488401
DESCRIPTIONEP0546073
DESCRIPTIONUS2003143204
DESCRIPTIONUS2003166282
DESCRIPTIONUS2003224432
DESCRIPTIONUS2003229905
DESCRIPTIONUS2004010810
DESCRIPTIONUS2004038278
DESCRIPTIONUS2004093622
DESCRIPTIONUS2005054055
DESCRIPTIONUS2005076395
DESCRIPTIONUS2005287630
DESCRIPTIONUS2006040363
DESCRIPTIONUS2006153836
DESCRIPTIONUS2006160726
DESCRIPTIONUS2007172483
DESCRIPTIONUS2007235029
DESCRIPTIONUS2008202513
DESCRIPTIONUS2008241223
DESCRIPTIONUS3710795
DESCRIPTIONUS4376110
DESCRIPTIONUS4634666
DESCRIPTIONUS4676980
DESCRIPTIONUS4686100
DESCRIPTIONUS4816567
DESCRIPTIONUS4863457
DESCRIPTIONUS4868116
DESCRIPTIONUS4980286
DESCRIPTIONUS4987071
DESCRIPTIONUS5093246
DESCRIPTIONUS5116742
DESCRIPTIONUS5223409
DESCRIPTIONUS5225539
DESCRIPTIONUS5403484
DESCRIPTIONUS5427908
DESCRIPTIONUS5501856
DESCRIPTIONUS5508717
DESCRIPTIONUS5545806
DESCRIPTIONUS5545807
DESCRIPTIONUS5569825
DESCRIPTIONUS5571698
DESCRIPTIONUS5591669
DESCRIPTIONUS5612205
DESCRIPTIONUS5625126
DESCRIPTIONUS5625825
DESCRIPTIONUS5633425
DESCRIPTIONUS5643763
DESCRIPTIONUS5661016
DESCRIPTIONUS5721367
DESCRIPTIONUS5770429
DESCRIPTIONUS5780279
DESCRIPTIONUS5789215
DESCRIPTIONUS5789650
DESCRIPTIONUS5814318
DESCRIPTIONUS5874299
DESCRIPTIONUS5877397
DESCRIPTIONUS5939598
DESCRIPTIONUS5997848
DESCRIPTIONUS6019968
DESCRIPTIONUS6040136
DESCRIPTIONUS6075181
DESCRIPTIONUS6114598
DESCRIPTIONUS6150584
DESCRIPTIONUS6162963
DESCRIPTIONUS6255458
DESCRIPTIONUS6300129
DESCRIPTIONUS6355245
DESCRIPTIONUS6657103
DESCRIPTIONUS6673986
DESCRIPTIONUS6680209
DESCRIPTIONUS6713610
DESCRIPTIONUS6794132
DESCRIPTIONUS6866845
DESCRIPTIONUS7041871
DESCRIPTIONUS7056897
DESCRIPTIONUS7112341
DESCRIPTIONUS7393648
DESCRIPTIONWO0034317
DESCRIPTIONWO0061178
DESCRIPTIONWO0069887
DESCRIPTIONWO0115731
DESCRIPTIONWO02069232
DESCRIPTIONWO2004108158
DESCRIPTIONWO2006122257
DESCRIPTIONWO2007024715
DESCRIPTIONWO2008024188
DESCRIPTIONWO8806630
DESCRIPTIONWO8902468
DESCRIPTIONWO8905345
DESCRIPTIONWO8907136
DESCRIPTIONWO9203918
DESCRIPTIONWO9207573
DESCRIPTIONWO9215679
DESCRIPTIONWO9222645
DESCRIPTIONWO9222647
DESCRIPTIONWO9222670
DESCRIPTIONWO9312227
DESCRIPTIONWO9400569
DESCRIPTIONWO9402602
DESCRIPTIONWO9425585
DESCRIPTIONWO9614436
DESCRIPTIONWO9627011
DESCRIPTIONWO9634096
DESCRIPTIONWO9708320
DESCRIPTIONWO9713852
DESCRIPTIONWO9824884
DESCRIPTIONWO9824893
OPPOSITIONEP2894165
OPPOSITIONWO2010054403
SEARCHUS2005191298

Non-Patent Literature (NPL) Citations (341) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- ABRERA-ABELEDA ET AL., J MED GENET, (2006), vol. 43, pages 582 - 589
DESCRIPTION- ABRERA-ABELEDA ET AL., JMED. GENET, (2006), vol. 43, pages 582 - 589
DESCRIPTION- AMES ET AL., J IMMUNOL, (1994), vol. 152, no. 9, pages 4572 - 4581
DESCRIPTION- AMES ET AL., J IMMUNOL, (1994), vol. 152, pages 4572 - 4581
DESCRIPTION- ANSEL ET AL., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed., LIPPINCOTT WILLIAMS & WILKINS PUBLISHERS, (1999), ISBN 0683305727
DESCRIPTION- APPEL ET AL., J AM. SOC NEPHROL., (2005), vol. 16, pages 1392 - 1404
DESCRIPTION- ARMENTANO ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 6141 - 6145
DESCRIPTION- ATHERSON ET AL., HEDICINE, (1998), vol. 77, no. 3, pages 195 - 207
DESCRIPTION- AULT ET AL., J BIOL. CHEM., (1997), vol. 272, pages 25168 - 75
DESCRIPTION- AVERY ET AL., AMERICAN JOURNAL OF HEMATOLOGY, (1998), vol. 58, pages 148 - 149
DESCRIPTION- BECKER ET AL., CLIN INFECT DIS, (2004), vol. 39, pages S267 - S275
DESCRIPTION- BELL ET AL., TRANSFUSION, (1973), vol. 13, no. 3, pages 138 - 141
DESCRIPTION- BENNY K. C. LO, Antibody Engineering: Methods and Protocols, HUMANA PRESS, (2004), ISBN 1588290921
DESCRIPTION- BENUCCI ET AL., CLIN RHEUMATOL, (2008), vol. 27, no. 11, pages 91 - 95
DESCRIPTION- BERGE ET AL., J. PHARM. SCI., (1977), vol. 66, pages 1 - 19
DESCRIPTION- BERKNER ET AL., BIOTECHNIQUES, (1988), vol. 6, page 616
DESCRIPTION- BILLY ET AL., PROC. NATL. ACAD. SCI. USA, (2001), vol. 98, pages 14428 - 14433
DESCRIPTION- BLOM ET AL., J IMMUNOL., (2008), vol. 180, no. 9, pages 6385 - 91
DESCRIPTION- BONEVA ET AL., J NEUROIMMUNOL., (2006), vol. 177, pages 119 - 131
DESCRIPTION- BRECCIA ET AL., EUR J HAEMATOL, (2004), vol. 73, no. 4, pages 304 - 6
DESCRIPTION- BRENNAN ET AL., SCIENCE, (1985), vol. 229, page 81
DESCRIPTION- BRESLIN ET AL., CLIN AM SOC NEPHROL, (2006), vol. 1, pages 88 - 99
DESCRIPTION- BRUGGEMANN ET AL., YEAR IN IMMUNOL, (1993), vol. 7, page 33
DESCRIPTION- BUNCH ET AL., ARCH DIS CHILD, (1972), vol. 47, no. 252, pages 299 - 300
DESCRIPTION- CANPOLAT ET AL., CLIN PEDIATR, (2008), vol. 47, no. 6, pages 593 - 7
DESCRIPTION- CAPRIOLI ET AL., AM SOC NEPHROL, (2001), vol. 12, pages 297 - 307
DESCRIPTION- CEPKO ET AL., CELL, (1984), vol. 37, page 1053
DESCRIPTION- CHANG ET AL., CATZCER GENET CYTOGENET, (2004), vol. 152, pages 66 - 69
DESCRIPTION- CHEN ET AL., INT. IMMUNOL., (1993), vol. 5, page 647
DESCRIPTION- CHEN ET AL., NATURE, (2007), vol. 446, no. 7132, pages 203 - 207
DESCRIPTION- CHOI ET AL., NATURE GENETICS, (1993), vol. 4, page 117
DESCRIPTION- CHOWDHURY ET AL., SCIENCE, (1991), vol. 254, pages 1802 - 1805
DESCRIPTION- CHRISTENSON; DACIE, BR J HAEMATOL, (1957), vol. 3, pages 153 - 164
DESCRIPTION- CHRISTENSON ET AL., BR J HAEMATOL, (1957), vol. 3, pages 262 - 275
DESCRIPTION- CLEMENS ET AL., PROC. NATL. ACAD. SCI. USA, (2000), vol. 97, pages 6499 - 6503
DESCRIPTION- COLVILLE ET AL., AM J KIDNEY DIS., (2003), vol. 42, pages E2 - 5
DESCRIPTION- CONSTANTINESCU ET AL., AM JKIDNEY DIS, (2004), vol. 43, pages 976 - 982
DESCRIPTION- COOPER ET AL., JEXP MED, (1970), vol. 132, pages 775 - 793
DESCRIPTION- COPELOVITCH; KAPLAN, PEDIATR-NEPHROL, (2008), vol. 23, no. 10, pages 1761 - 7
DESCRIPTION- CURR OPIR HEMATOL, (2007), vol. 14, no. 3, pages 277 - 283
DESCRIPTION- DACIE ET AL., BR JHAEMATOL, (1957), vol. 3, pages 77 - 87
DESCRIPTION- DAI ET AL., PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, pages 10892 - 10895
DESCRIPTION- DAMERAU ET AL., MOLEC. IMMUNOL., (1989), vol. 26, pages 1133 - 1142
DESCRIPTION- DANOS; MULLIGAN, PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 6460 - 6464
DESCRIPTION- DAVIS ET AL., CANCER METASTASIS REV., (1999), vol. 18, no. 4, pages 421 - 5
DESCRIPTION- DEANS ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, page 1292
DESCRIPTION- DE LA CRUZ ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, (1988), vol. 263, pages 4318 - 4322
DESCRIPTION- DONG ET AL., ARN J HEMATOL., (2008), vol. 83, no. 10, pages 815 - 817
DESCRIPTION- DRAGON-DUREY ET AL., JAM SOC NEPHROT, (2005), vol. 16, pages 555 - 63
DESCRIPTION- DROSOS ET AL., CLIN EXP RHEUMATOL., (1993), vol. 11, no. 4, pages 387 - 91
DESCRIPTION- DUCHOSAL ET AL., NATURE, (1992), vol. 355, page 258
DESCRIPTION- EDER, IMMUNOHEMATOLOGY, (2005), vol. 21, no. 2, pages 56 - 62
DESCRIPTION- EGLITIS ET AL., SCIENCE, (1985), vol. 230, pages 1395 - 1398
DESCRIPTION- ELBASHIR ET AL., NATURE, (2001), vol. 411, pages 494 - 8
DESCRIPTION- ESPARZA-GORDILLO ET AL., HUM MOL GENET, (2005), vol. 14, pages 703 - 712
DESCRIPTION- EVANS ET AL., MOL. INIMUNOL., (1995), vol. 32, no. 16, pages 1183 - 95
DESCRIPTION- FEARON ET AL., J EXP MED, (1975), vol. 142, pages 856 - 863
DESCRIPTION- FERRY ET AL., PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, pages 8377 - 8381
DESCRIPTION- FINLAND; BARNES, AMA ARCH INTERN MED, (1958), vol. 191, pages 462 - 466
DESCRIPTION- FISHWILD ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, page 845
DESCRIPTION- FLOTTE ET AL., AM. J. RESPIR. CELL. MOL. BIOL., (1992), vol. 7, pages 349 - 356
DESCRIPTION- FREMEAUX-BACCHI ET AL., JAM SOC NEPHROL, (2005), vol. 17, pages 2017 - 2025
DESCRIPTION- FREMEAUX-BACCHI ET AL., J MEDICAL GENET, (2004), vol. 41, page E84
DESCRIPTION- FUNATO ET AL., EUR J HAEMATOL, (2007), vol. 79, no. 5, page 462
DESCRIPTION- FURLAN ET AL., NEW ENGL J MED., (1998), vol. 339, pages 1578 - 1584
DESCRIPTION- G6MEZ-PUERTA ET AL., AUTOIMMUNE REV., (2006), vol. 6, no. 2, pages 85 - 8
DESCRIPTION- G6MEZ-PUERTA ET AL., SEMIN. ARTHRITIS RHEUM., (2006), vol. 35, no. 5, pages 322 - 32
DESCRIPTION- GARRATTY, TRANSFUSION, (2001), vol. 41, no. 8, pages 1073 - 4
DESCRIPTION- GENNARO, Remington: The Science and Practice of Pharmacy, 20th ed., LIPPINCOTT, WILLIAMS & WILKINS, (2000), ISBN 0683306472
DESCRIPTION- GEORGE, CURR OPIN HEMATOL, (2003), vol. 10, pages 339 - 344
DESCRIPTION- GERTZ, HEMATOLOGY, (2006), vol. 1, pages 19 - 23
DESCRIPTION- GIANNINI ET AL., JBIOL CHEM, (1995), vol. 270, no. 32, pages 19166 - 19172
DESCRIPTION- GLEICHER; BUTTINO, Principles & Practice of Medical Therapy in Pregnancy, 3rd ed., APPLETON & LANGE, (1998), ISBN 083857677X
DESCRIPTION- GOICOECHEA DE JORGE ET AL., PROC NATL ACAD SCI USA, (2007), vol. 104, no. 1, pages 240 - 245
DESCRIPTION- GOICOECHEA DE JORGE ET AL., PROC NATL ACAD SCI USA, (2007), vol. 104, pages 240 - 245
DESCRIPTION- GORDON ET AL., SEMINARS IN HEMATOLOGY, (1997), vol. 34, no. 2, pages 140 - 147
DESCRIPTION- GOTTSCHALL ET AL., AM J HEMATOL, (1994), vol. 47, pages 283 - 289
DESCRIPTION- GREEN; JAKOBOVITS, J. EXP. MED., (1998), vol. 188, pages 483 - 495
DESCRIPTION- GRUBER ET AL., J. IMMUNOL., (1994), vol. 152, page 5368
DESCRIPTION- "Guidelines in Electrodiagnostic Medicine. American Association of Electrodiagnostic Medicine", MUSCLE NERVE, vol. 15, pages 229 - 253
DESCRIPTION- HABIB ET AL., KIDNEY IN.T., (1975), vol. 7, pages 204 - 215
DESCRIPTION- HABIB ET AL., LMMUNOLLNVEST, (2007), vol. 37, no. 8, pages 849 - 857
DESCRIPTION- HAGEMANN ET AL., J BIOL CHEM, (2008), vol. 283, no. 12, pages 7763 - 75
DESCRIPTION- HANOUSKA ET AL., CLIN CANCER RES, (2007), vol. 13, no. 2, pages 523 - 531
DESCRIPTION- HASELHOFF; GERLACH, NATUR-E, (1988), vol. 334, pages 585 - 59
DESCRIPTION- HAVILAND ET AL., J. IMMUNOL., (1991), vol. 146, pages 362 - 368
DESCRIPTION- HEGASY ET AL., AM J PATHOL, (2002), vol. 161, pages 2027 - 2034
DESCRIPTION- HELENE, ANN. NY. ACAD. SCI., (1992), vol. 660, pages 27 - 36
DESCRIPTION- HELENE, C., ANTICANCER DRUG D, (1991), vol. 6, pages 569 - 84
DESCRIPTION- HETHERINGTON ET AL., ANTIMICROBIAL AGENTS AND CHERNOTHERAPY, (2006), vol. 50, no. 10, pages 3499 - 3500
DESCRIPTION- HILL, CLIN ADV HEMATOL ONCOL, (2005), vol. 3, no. 11, pages 849 - 50
DESCRIPTION- HILL ET AL., BLOOD, (2005), vol. 106, no. 7, page 2559
DESCRIPTION- HILLMEN ET AL., N ENGL J MED, (2004), vol. 350, no. 6, page 552
DESCRIPTION- HILLMEN ET AL., N ENGL JMED, (2004), vol. 350, no. 6, page 552
DESCRIPTION- HOCH ET AL., NATMED, (2001), vol. 7, pages 365 - 368
DESCRIPTION- HOLERS ET AL., IMMUNOLOGICAL REVIEWS, (2008), vol. 223, pages 300 - 316
DESCRIPTION- HOLERS, IMMURCOLOGICAL REVIEWS, (2008), vol. 223, pages 300 - 316
DESCRIPTION- HOLERS; THURMAN, MOLECULAR IMMUNOLOGY, (2004), vol. 41, pages 147 - 152
DESCRIPTION- HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
DESCRIPTION- HOOGENBOOM ET AL., J. MOL. BIOL., (1991), vol. 227, page 381
DESCRIPTION- HORWITZ ET AL., BLOOD, (1977), vol. 50, pages 195 - 202
DESCRIPTION- HUBER ET AL., PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, pages 8039 - 8043
DESCRIPTION- HUDSON ET AL., J. IMMUNOL. METHODS, (1999), vol. 23, no. 1-2, pages 177 - 189
DESCRIPTION- HUSTON ET AL., HUM. ANTIBODIES, (2001), vol. 10, no. 3-4, pages 127 - 142
DESCRIPTION- HWU ET AL., J. IMMUNOL, (1993), vol. 150, pages 4104 - 4115
DESCRIPTION- IDEGUCHI ET AL., LUPUS, (2007), vol. 16, no. 1, pages 59 - 64
DESCRIPTION- INOUE, COMPLEMENT INFLAMM, (1989), vol. 6, no. 3, pages 219 - 222
DESCRIPTION- ISENMAN ET AL., J IMMUNOL, (1980), vol. 124, pages 326 - 331
DESCRIPTION- ISENMAN ET AL., JLMMUNOL., (1980), vol. 124, no. 1, pages 326 - 31
DESCRIPTION- JAKOBOVITS ET AL., NATURE, (1993), vol. 362, pages 255 - 258
DESCRIPTION- JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, page 2551
DESCRIPTION- J. AM. CHEM. SOC., (1998), vol. 120, pages 8565 - 8566
DESCRIPTION- JANSEN ET AL., KIDNEY INT., (1998), vol. 53, pages 331 - 349
DESCRIPTION- JOHNE ET AL., J. IMMUNOL. METH., (1993), vol. 160, pages 191 - 198
DESCRIPTION- JOHNE ET AL., J. IMMUNOL. METHODS, (1993), vol. 160, pages 20191 - 8
DESCRIPTION- JONESET, NATURE, (1986), vol. 321, pages 522 - 525
DESCRIPTION- JONSSON ET AL., ANN. BIOL. CLIN., (1993), vol. 51, pages 19 - 26
DESCRIPTION- JONSSON ET AL., BIOTECHNIQUES, (1991), vol. 11, pages 620 - 627
DESCRIPTION- JULKUNEN ET AL., SCAN JRHEUMATOL, (2005), vol. 34, no. 2, pages 122 - 124
DESCRIPTION- KABAT AND MAYER, Experimental Immunochemistry, 2nd ed., SPRINGFIELD, (1961), pages 135 - 139
DESCRIPTION- KAESER ET AL., ACTA NEUNOL SCAND SUPPL., (1984), vol. 100, pages 39 - 47
DESCRIPTION- KANEKO ET AL., IMMUNOLOGY, (1995), vol. 86, no. 1, pages 149 - 154
DESCRIPTION- KAPLAN, CURR OPIN INVESTIG DRUGS, (2002), vol. 3, no. 7, pages 1017 - 23
DESCRIPTION- KASAMON ET AL., HAEMATODOGIA, (2005), vol. 90, no. 3, pages 50 - 53
DESCRIPTION- KATIRJI ET AL., NEUROL CLIN, (2002), vol. 20, pages 557 - 586
DESCRIPTION- KAUFMAN, PROC. NATL. ACAD. SCI. USA, (1985), vol. 82, page 689
DESCRIPTION- KAY ET AL., HUMAN GENE THERAPY, (1992), vol. 3, pages 641 - 647
DESCRIPTION- KIBBE, Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3rd ed., (2000), ISBN 091733096X
DESCRIPTION- KOHLER; MILSTEIN, NATUR-E, (1975), vol. 256, pages 495 - 497
DESCRIPTION- KOKAME ET AL., SEMIN. HEMATOL., (2004), vol. 41, pages 34 - 40
DESCRIPTION- KOSTELNY ET AL., J. IMMUNOL., (1992), vol. 148, no. 5, pages 1547 - 1553
DESCRIPTION- KOSTELNY ET AL., J. LININUITOL, (1992), vol. 148, no. 5, pages 1547 - 1553
DESCRIPTION- LEVY ET AL., NATURE, (2001), vol. 413, pages 488 - 494
DESCRIPTION- LICHT ET AL., KIDNEY FIIT., (2006), vol. 70, pages 42 - 50
DESCRIPTION- LICHT ET AL., KIDNEY INT., (2004), vol. 66, pages 955 - 958
DESCRIPTION- LICHT ET AL., KIDNEY INT., (2006), vol. 70, pages 42 - 50
DESCRIPTION- LINDGREN ET AL., TRANSFUSION, (1985), vol. 25, no. 2, pages 142 - 4
DESCRIPTION- LONBERG ET AL., NATURE, (1994), vol. 368, pages 856 - 859
DESCRIPTION- LUDWIG ET AL., J CLIU MICROBIOL, (2001), vol. 39, no. 6, pages 2272 - 2279
DESCRIPTION- LUSKY; BOTCHAN, NATURE, (1981), vol. 293, page 79
DESCRIPTION- MAHER, BIOASSAYS, (1992), vol. 14, pages 807 - 15
DESCRIPTION- MANNER ET AL., AM J MED SCI, (2008), vol. 335, no. 5, pages 394 - 397
DESCRIPTION- MANNER ET AL., AM T MED. SCI., (2008), vol. 335, no. 5, pages 394 - 7
DESCRIPTION- MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 597
DESCRIPTION- MARY; BOULAY, EUR JHAEMATOL, (1993), vol. 51, no. 5, pages 282 - 287
DESCRIPTION- MATSUMOTO ET AL., BLOOD, (2004), vol. 103, pages 1305 - 1310
DESCRIPTION- MCCONVILLE ET AL., ANN. NEUROL., (2004), vol. 55, pages 580 - 584
DESCRIPTION- MCLAUGHLIN ET AL., J. VIROL, (1989), vol. 62, pages 1963 - 1973
DESCRIPTION- MEDICUS ET AL., J EXP MED, (1976), vol. 144, pages 1076 - 1093
DESCRIPTION- MENDEZ ET AL., NATURE GENETICS, (1998), vol. 15, pages 146 - 156
DESCRIPTION- MICHAUX ET AL., ANN HEMATOL, (1998), vol. 76, pages 201 - 204
DESCRIPTION- MIESBACH ET AL., AUTOIMMUNE REV., (2006), vol. 6, no. 2, pages 94 - 7
DESCRIPTION- MIILLER-EBERHARD, BIOCHEM SOC SYMP, (1985), vol. 50, pages 235 - 246
DESCRIPTION- MILSTEIN; CUELLO, NATURE, (1983), vol. 305, pages 537 - 539
DESCRIPTION- MINTA; MAN, J IMMUNOL., (1997), vol. 119, pages 1597 - 1602
DESCRIPTION- MIRALBELL ET AL., J CLIN ONCOL, (1996), vol. 14, pages 579 - 585
DESCRIPTION- MIYAWAKI ET AL., J RHEUMATOL, (2005), vol. 32, no. 8, pages 1488 - 1494
DESCRIPTION- MOLLNES ET AL., SCAND. J. IMMUNOL., (1988), vol. 28, pages 307 - 312
DESCRIPTION- MOONGKARNDI ET AL., IMMUNOBIOL, (1982), vol. 162, page 397
DESCRIPTION- MOONGKARNDI ET AL., IMMUNOBIOL., (1982), vol. 162, page 397
DESCRIPTION- MOONGKARNDI ET AL., IMMUNOBIOL, (1983), vol. 165, page 323
DESCRIPTION- MOONGKARNDI ET AL., IMMUNOBIOL., (1983), vol. 165, page 323
DESCRIPTION- MOONGKARNDI ET AL., IMMU .OBIOL., (1983), vol. 165, page 323
DESCRIPTION- MORI ET AL., TRANSFUSION, (2002), vol. 42, pages 572 - 580
DESCRIPTION- MULLER-EBERHARD, ANN REV BIOCHEM, (1988), vol. 57, pages 321 - 347
DESCRIPTION- MULLIGAN; BERG, PROC. NATL. ACAD. SCI. USA, (1981), vol. 78, page 2072
DESCRIPTION- NEUMAN ET AL., JMED GENET, (2003), vol. 40, pages 676 - 681
DESCRIPTION- NIIMBERGER ET AL., N ENGL JMED, (2009), vol. 360, no. 5, pages 542 - 544
DESCRIPTION- NORDHAGEN ET AL., ACTA PAEDIATR. SCAND, (1984), vol. 73, no. 2, pages 258 - 262
DESCRIPTION- NORDHAGEN ET AL., TRATZSFUSION, (1991), vol. 31, no. 2, pages 190 - 1
DESCRIPTION- NORIS ET AL., J. AM. SOC. NEPHROL., (2005), vol. 16, pages 1177 - 1183
DESCRIPTION- OKAYAMA; BERG, MOL. CELL BIOL., (1983), vol. 3, page 280
DESCRIPTION- OSTBERG ET AL., HYBRIDOMA, (1983), vol. 2, pages 361 - 367
DESCRIPTION- PADDEN ET AL., AM FAM PHYSICIAN, (1999), vol. 60, no. 3, pages 829 - 836
DESCRIPTION- PAPALIA ET AL., BR J HAEMATOL, (2000), vol. 109, no. 2, pages 328 - 9
DESCRIPTION- PARMLEY; SMITH, GENE, (1988), vol. 73, pages 305 - 318
DESCRIPTION- PASCUZZI, SEMIN NEUROL, (2003), vol. 23, no. 1, pages 83 - 88
DESCRIPTION- PATEL ET AL., DRUGS TODAY (BARC, (2005), vol. 41, no. 3, pages 165 - 70
DESCRIPTION- POLJAK, STRUCTURE, (1994), vol. 2 12, pages 1121 - 1123
DESCRIPTION- POZNANSKY ET AL., J LMMUNOL., (1989), vol. 143, pages 1254 - 1258
DESCRIPTION- RICHARDS ET AL., AM JHUM GENET, (2001), vol. 68, pages 485 - 490
DESCRIPTION- RICHARDS ET AL., PROC NATL ACAD SCI USA, (2006), vol. 100, pages 12966 - 12971
DESCRIPTION- RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 327
DESCRIPTION- ROMI ET AL., ARCH NEUROL., (2005), vol. 62, pages 442 - 446
DESCRIPTION- ROSENFELD ET AL., CELL, (1992), vol. 68, pages 143 - 155
DESCRIPTION- ROSENFELD ET AL., SCIENCE, (1991), vol. 252, pages 431 - 434
DESCRIPTION- ROTHER ET AL., NATURE BIOTECHNOLOGY, (2007), vol. 25, no. 11, pages 1256 - 1488
DESCRIPTION- SAHIN ET AL., NAGOYA MED J, (2001), vol. 44, no. 3, pages 145 - 152
DESCRIPTION- SAMULSKI ET AL., J. VIROL., (1989), vol. 63, pages 3822 - 3828
DESCRIPTION- SARVER ET AL., PROC. NATL. ACAD. SCI. USA, (1982), vol. 79, page 7147
DESCRIPTION- SCHOCKETT ET AL., PROC NATL ACAD SCI USA, (1996), vol. 93, pages 5173 - 5176
DESCRIPTION- SCHREIBER ET AL., PROC NATLACAD SCI USA, (1978), vol. 75, pages 3948 - 3952
DESCRIPTION- SCHWERTZ ET AL., PEDIATRALLERGY IMMUNO ., (2001), vol. 12, pages 166 - 172
DESCRIPTION- SETHI ET AL., NEUROLOGY, (1987), vol. 37, no. 8, pages 1383 - 1385
DESCRIPTION- SHALABY ET AL., J. EXP. MED., (1992), vol. 175, pages 217 - 225
DESCRIPTION- SHARARA ET AL., SOUTH MED J., (1994), vol. 87, no. 3, pages 397 - 9
DESCRIPTION- SIBAI, AM J OBSTET GYNECOL, (1986), vol. 162, pages 311 - 316
DESCRIPTION- SISSONS ET AL., PROC NATL ACAD SCI USA, (1980), vol. 77, pages 559 - 562
DESCRIPTION- SIVAKUMARAN ET AL., BR J HAEMATOL, (1999), vol. 105, no. 1, pages 278 - 9
DESCRIPTION- SMITH, SCIENCE, (1985), vol. 225, pages 1315 - 1317
DESCRIPTION- SOKOL ET AL., ACTA HAEMATOL, (1982), vol. 68, no. 4, pages 268 - 277
DESCRIPTION- SOKOL ET AL., ACTA HAEMATOL, (1984), vol. 72, no. 4, pages 245 - 257
DESCRIPTION- SOKOL ET AL., IMMUFZOHEMATOLOGY, (1998), vol. 14, no. 3, pages 109 - 12
DESCRIPTION- SOLT6SZ ET AL., HAEMATOLOGIA (BUDEP), (2000), vol. 30, no. 4, pages 303 - 311
DESCRIPTION- SOUTHERN; BERG, MOL. APPL. GENET., (1982), vol. 1, page 327
DESCRIPTION- STAELENS ET AL., MOL IMMUNOL, (2006), vol. 43, pages 1243 - 1257
DESCRIPTION- STOCKS, DRUG DISCOV. TODAY, (2004), vol. 9, no. 22, pages 960 - 966
DESCRIPTION- SULLIVAN ET AL., AM J OBSTET GYNECOL, (1994), vol. 171, pages 940 - 943
DESCRIPTION- SURESH ET AL., METHODS IN ENZYMOLOGY, (1986), vol. 121, page 210
DESCRIPTION- TAYLOR ET AL., INTERNATIONAL IMMUNOLOGY, (1994), vol. 6, pages 579 - 591
DESCRIPTION- TAYLOR ET AL., NUCLEIC ACIDS RES., (1992), vol. 20, page 6287
DESCRIPTION- TAYLOR ET AL., NUCLEIC ACIDS RESEARCH, (1992), vol. 20, pages 6287 - 6295
DESCRIPTION- ., The Merck Manual, 16th ed., .
DESCRIPTION- "The role of complement in membranoproliferative glomerulonephritis", ZIPFEL ET AL., Complement and Kidney Disease, SPRINGER, (2006), pages 199 - 221
DESCRIPTION- THOMAS ET AL., MOL IMMUNOL., (1996), vol. 33, no. 17-18, pages 1389 - 401
DESCRIPTION- THOMAS ET AL., MOL. IMMUNOL., (1996), vol. 33, no. 17-18, pages 1389 - 401
DESCRIPTION- TOMIZUKA ET AL., PROC. NATL. ACAD. SCI. USA, (2000), vol. 97, no. 2, pages 722 - 727
DESCRIPTION- TOMSEN, AM J OBSTET GYNECOL, (1995), vol. 172, pages 1876 - 1890
DESCRIPTION- TSAI, J. AM. SOC. NEPHROL, (2003), vol. 14, pages 1072 - 1081
DESCRIPTION- TUAILLON ET AL., EUR. J. IMMUNOL., (2000), vol. 10, pages 2998 - 3005
DESCRIPTION- TUAILLON ET AL., J. IMMUNOL., (1995), vol. 154, pages 6453 - 65
DESCRIPTION- TUAILLON ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 3720 - 4
DESCRIPTION- TUTT ET AL., J. IMMUNOL., (1991), vol. 147, page 60
DESCRIPTION- ULRICH, Handb Exp Pharmacol., (2006), vol. 173, pages 305 - 326
DESCRIPTION- VALAVAARA ET AL., CANCER, (1985), vol. 55, pages 47 - 50
DESCRIPTION- VAN BEUSECHEM ET AL., PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, pages 7640 - 7644
DESCRIPTION- VAN GURP ET AL., AM J TRAASPLANTATION, (2008), vol. 8, no. 8, pages 1711 - 1718
DESCRIPTION- VAN VENROOIJ ET AL., ANN NYACAD SCI, (2008), vol. 1143, pages 268 - 285
DESCRIPTION- VAUGHAN ET AL., NATURE BIOTECH, (1996), vol. 14, page 309
DESCRIPTION- VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536
DESCRIPTION- VINCENT ET AL., SEMIN NEUROL., (2004), vol. 24, pages 125 - 133
DESCRIPTION- WALKER ET AL., MOD. PATHOL., (2007), vol. 20, pages 605 - 616
DESCRIPTION- WANG ET AL., ACTA PAEDIATR TAIWAN, (2004), vol. 45, pages 293 - 295
DESCRIPTION- WARD, JMOI MED, (2009), vol. 87, no. 4, pages 375 - 378
DESCRIPTION- WARD; ZVAIFLER, J CLIN INVEST, (1971), vol. 50, no. 3, pages 606 - 16
DESCRIPTION- WARD; ZVAIFLER, J CLIN INVEST., (1971), vol. 50, no. 3, pages 606 - 16
DESCRIPTION- WARWICKER ET AL., KIDNEY INT., (1998), vol. 53, pages 836 - 844
DESCRIPTION- WETSEL; KOLB, J LMMUNOL., (1982), vol. 128, pages 2209 - 2216
DESCRIPTION- WHEELER ET AL., MOL THER, (2003), vol. 8, no. 3, pages 355 - 366
DESCRIPTION- WHISS, CURR OPIN INVESTIG DRUGS, (2002), vol. 3, no. 6, pages 870 - 7
DESCRIPTION- WIGLER ET AL., CELL, (1979), vol. 16, page 77
DESCRIPTION- WILSON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 3014 - 3018
DESCRIPTION- WIN ET AL., TRANSFUS MED., (2005), vol. 15, no. 3, page 254
DESCRIPTION- WU ET AL., NAT BIOTECHNOL, (2007), vol. 25, no. 11, pages 1290 - 1297
DESCRIPTION- WURZNER ET AL., COMPLEMENT INFLAMM, (1991), vol. 8, pages 328 - 340
DESCRIPTION- WURZNER ET AL., COMPLEMENT INFLAMM., (1991), vol. 8, pages 328 - 340
DESCRIPTION- WYNN ET AL., CLIN LAB HAEMATOL, (1998), vol. 20, no. 6, pages 373 - 5
DESCRIPTION- YAMAMOTO; GEWURZ, J IMMUNOL., (1978), vol. 120, page 2008
DESCRIPTION- YAMAMOTO; GEWURZ, J LMMUUOL, (1978), vol. 120, no. 6, pages 2008 - 2015
DESCRIPTION- YANG ET AL., PROC. NATL. ACAD. SCI. USA, (2002), vol. 99, pages 9942 - 9947
DESCRIPTION- ZAPATA ET AL., PROTEIN ENG., (1995), vol. 8, no. 10, pages 1057 - 1062
DESCRIPTION- ZIMAN ET AL., TRANSFUSION, (2004), vol. 44, no. 8, pages 1127 - 1128
DESCRIPTION- ZIPFEL, Complement and Kidney Disease, SPRINGER, (2005), ISBN 3764371668
DESCRIPTION- ZUIDERWEG ET AL., BIOCHENIISTRY, (1989), vol. 28, no. 1, pages 172 - 85
EXAMINATION- Anonymous, "Assessment report Soliris eculizumab Procedure No.: EMEA/H/C/000791/II/0027", 22 September 2011 EXT/834951/2011 Corr1 Committee for Medicinal Products for Human Use (CHMP), (20150101), page 5555, URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000791/WC500119185.pdf, (20180719), XP055493808
EXAMINATION- Anonymous, "Atypical hemolytic uremic syndrome - Wikipedia", wikipedia, (20161220), URL: https://en.wikipedia.org/wiki/Atypical_hemolytic_uremic_syndrome, (20161220), XP055330648
EXAMINATION- GILLIAN M. KEATING, "Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome", DRUGS, NZ, (20131201), vol. 73, no. 18, doi:10.1007/s40265-013-0147-7, ISSN 0012-6667, pages 2053 - 2066, XP055493804
EXAMINATION- RICKLIN DANIEL ET AL, "Complement-targeted therapeutics", NATURE BIOTECHNOLOGY, GALE GROUP INC, US, vol. 25, no. 11, doi:10.1038/NBT1342, ISSN 1087-0156, (20071101), pages 1265 - 1275, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966895/, (20071107), XP002546813
EXAMINATION- A. AVILA ET AL, "Remission of aHUS neurological damage with eculizumab", CLINICAL KIDNEY JOURNAL, (20150122), vol. 8, no. 2, doi:10.1093/ckj/sfu144, ISSN 2048-8505, pages 232 - 236, XP055394181
EXAMINATION- CHATELET VALERIE ET AL, "Efficacy of Eculizumab in a Plasmatherapy-Dependent Patient with Atypical Hemolytic Uremic Syndrome with C3 Mutation Following Plasmatherapy Withdrawal", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20081116), vol. 112, no. 11, doi:10.1182/BLOOD.V112.11.4579.4579, ISSN 0006-4971, page 4579, XP086679334
OPPOSITION- Alexion Pharmaceuticals, Inc. , "Trade Name: Soliris; Generic Name: Eculizumab", Approval Package for: APPLICATION NUMBER: 125166s172, FDA; CENTER FOR DRUG EVALUATION AND RESEARCH, US, US, (20110923), pages 1 - 780, XP009553979
OPPOSITION- Andreoli Sharon Philip, Bernd Zimmerhackl, "Chapter 25: Hemolytic Uremic Syndrome", PEDIATRIC NEPHROLOGY., DE , SPRINGER VERLAG, BERLIN. , (20080101), vol. 38, pages 359 - 384, ISSN 0931-041X, XP093138307
OPPOSITION- Anne-Laure Lapeyraque ; Eric Wagner ; Véronique Phan ; Marie-José Clermont ; Aà ̄cha Merouani ; Véronique Frémeaux-Bacchi ; Timothy H. J. Goodship ; Pierre Robitaille, "Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations", Pediatric Nephrology ; Journal of the International Pediatric Nephrology Association, Springer, Berlin, DE, Berlin, DE , (20080419), vol. 23, no. 8, ISSN 1432-198X, pages 1363 - 1366, XP019631973
OPPOSITION- Anonymous, "American Society ofNephrology Abstracts2Vicw(TM)", ASN, (20081110), ASN, (20240307), XP093138842
OPPOSITION- Anonymous, "A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)", ClinicalTrials.gov Identifier: NCT01770951, (20130118), ClinicalTrials.gov Identifier: NCT01770951, URL: https://classic.clinicaltrials.gov/ct2/show/NCT01770951, (20240306), XP093138275
OPPOSITION- Anonymous, "A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)", Clinicaltrials.gov ID NCT01770951, (20230818), pages 1 - 7, Clinicaltrials.gov ID NCT01770951 , URL: https://clinicaltrials.gov/study/NCT01770951, (20240307), XP093138867
OPPOSITION- Anonymous, "General Information", ASH Publications and Meeting Materials - American Society of Hematology, (20080914), ASH Publications and Meeting Materials - American Society of Hematology, URL: www.hematology.org:80/meetings/2008/attendees/publications.cfm, (20240307), XP093138879
OPPOSITION- Anonymous, "JASN abstracts November 4-November 9, 2008 -Philadelphia, PA, USA", ASN, (20230503), ASN, (20240307), XP093138836
OPPOSITION- Anonymous, "Onsite Program", ASN Renal Week 2008, (20081031), ASN Renal Week 2008, (20240307), XP093138821
OPPOSITION- Anonymous, "Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant Atypical Hemolytic", ClinicalTrials.gov Identifier: NCT00844844, (20090901), ClinicalTrials.gov Identifier: NCT00844844, URL: http://clinicaltrials.gov/ct2/show/NCT00844844, (20240307), XP093139007
OPPOSITION- Anonymous, "Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive Atypical Hemolytic Uremic S", ClinicalTrials.gov Identifier: NCT00844428, (20060901), ClinicalTrials.gov Identifier: NCT00844428, URL: http://clinicaltrials.gov/ct2/show/NCT00844428, (20240307), XP093139000
OPPOSITION- Anonymous, "Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant Atypical Hemolytic Uremic Syndrome (aHUS)", ClinicalTrials.gov Identifier: NCT00844545, (20090901), ClinicalTrials.gov Identifier: NCT00844545, URL: http://clinicaltrials.gov/ct2/show/NCT00844545, (20240307), XP093139011
OPPOSITION- Anonymous, "Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)", ClinicalTrials.gov Identifier:: NCT00838513, (20091111), ClinicalTrials.gov Identifier:: NCT00838513, URL: http://clinicaltrials.gov/ct2/show/NCT00838513, (20240307), XP093139003
OPPOSITION- Anonymous, "Record History Tab NCT00838513", Clinicaltrials.gov, (20090204), Clinicaltrials.gov, URL: https://clinicaltrials.gov/study/NCT00838513?cond=aHUS%2520-%2520&tab=history, (20240307), XP093138779
OPPOSITION- Anonymous, "Record History Tab NCT00838513", Clinicaltrials.gov, (20090928), Clinicaltrials.gov, URL: https://clinicaltrials.gov/study/NCT00838513?cond=aHUS%2520-%2520&tab=history, (20240307), XP093138769
OPPOSITION- Anonymous, "Record History Tab NCT00844428", Clinicaltrials.gov, (20090213), Clinicaltrials.gov, URL: https://clinicaltrials.gov/study/NCT00844428?cond=aHUS%2520-%2520&tab=history, (20240307), XP093138782
OPPOSITION- Anonymous, "Record History Tab NCT00844428", Clinicaltrials.gov, (20090928), Clinicaltrials.gov, URL: https://clinicaltrials.gov/study/NCT00844428?cond=aHUS%2520-%2520&tab=history, (20240307), XP093138770
OPPOSITION- Anonymous, "Record History Tab NCT00844545", Clinicaltrials.gov, (20090213), Clinicaltrials.gov, URL: https://clinicaltrials.gov/study/NCT00844545?cond=aHUS%2520-%2520, (20240307), XP093138772
OPPOSITION- Anonymous, "Record History Tab NCT00844545", Clinicaltrials.gov, (20090923), Clinicaltrials.gov, URL: https://clinicaltrials.gov/study/NCT00844545?cond=aHUS%2520-%2520&tab=history, (20240307), XP093138761
OPPOSITION- Anonymous, "Record History Tab NCT00844844", Clinicaltrials.gov, (20090213), Clinicaltrials.gov, URL: https://clinicaltrials.gov/study/NCT00844844?cond=aHUS%2520-%2520&tab=history, (20240307), XP093138774
OPPOSITION- Anonymous, " Record History Tab NCT00844844", Clinicaltrials.gov, (20090928), Clinicaltrials.gov, URL: https://clinicaltrials.gov/study/NCT00844844?cond=aHUS%2520-%2520&tab=history, (20240307), XP093138764
OPPOSITION- Anonymous, "Renal Week 2008", ASN preliminary program, (20081031), ASN preliminary program , (20240307), XP093138820
OPPOSITION- Anonymous, "Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting", Alexio - Press release, (20081110), Alexio - Press release , URL: https://media.alexion.com/news-releases/news-release-details/researchers-present-additional-data-solirisr-eculizumab, (20240307), XP093138877
OPPOSITION- Anonymous, "Unterlassungsanspruch wegen der Beeinträchtigung eines orphan drugsMarktexklusivitätsrechts", GRUR-RS 2023, 23966, (20230804), GRUR-RS 2023, 23966, URL: https://beck-online.beck.de/Dokument?vpath=bibdata%2Fents%2Fgrurrs%2F2023%2Fcont%2Fgrurrs.2023.23966.htm&anchor=Y-300-Z-GRURRS-B-2023-N-23966, (20240306), XP093138327
OPPOSITION- Brody Tom, "Duty to Disclose: Dayco Products v. Total Containment", The John Marshall Review of Intellectual Property Law, (20080101), pages 325 - 375, XP093138863
OPPOSITION- Coffman Thomas M, "Ambitious Goals Set for ASN in 2009", ASN Kidney News, (20090101), pages 20 - 21, ASN Kidney News, URL: https://www.kidneynews.org/downloadpdf/view/journals/kidney-news/1/1/article-p20_27.pdf, (20240307), XP093138844
OPPOSITION- Ema, "Assessment report Soliris eculizumab", EMEA/H/C/000791/II/0027, (20110922), pages 1 - 115, EMEA/H/C/000791/II/0027, (20240306), XP093138325
OPPOSITION- Ema, "Soliris 300 mg concentrate for solution for infusion (Eculizumab)", ANNEXI SUMMARY OF PRODUCT CHARACTERISTICS, (20070101), pages 1 - 29, ANNEXI SUMMARY OF PRODUCT CHARACTERISTICS , URL: https://www.ema.europa.eu, (20240307), XP093138860
OPPOSITION- Ema, "Soliris : EPAR - Product Information", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, (20090701), pages 1 - 60, ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, (20240307), XP093138875
OPPOSITION- Goicoechea De Jorge Elena, Danielle Paixao-Cavalcante, Kirsten L. Rose, H. Terence Cook, Marina Botto, Matthew C. Pickering, "C5 activation is required for the development of atypical haemolytic uraemic syndrome in Cfh-/--FHA16-20 mic", Abstracts /MolecularImmunology, (20080101), vol. 45, pages 4100 - 4101, XP093138313
OPPOSITION- Goicoechea De Jorge Elena, Paixao-Cavalcante D; Rose K L; Cook H T; Botto M; Pickering M C , "C5 activation is required for the development of atypical haemolytic uraemic syndrome in Cfh-/--FHA16-20 mice", Presentatiom, Imperial College School of Medicine, London, UK, Imperial College School of Medicine, London, UK, (20080101), pages 1 - 21, Presentatiom, (20240306), XP093138316
OPPOSITION- Joyce Geelen ; Koen van den Dries ; Anja Roos ; Nicole van de Kar ; Corrie de Kat Angelino ; Ina Klasen ; Leo Monnens ; Lambertus van den Heuvel, "A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome", Pediatric Nephrology ; Journal of the International Pediatric Nephrology Association, Springer, Berlin, DE, Berlin, DE , (20061115), vol. 22, no. 3, ISSN 1432-198X, pages 371 - 375, XP019492427
OPPOSITION- Richard Kelly, Louise Arnold, Stephen Richards, Anita Hill, Sandra Vanbijnen, Petra Muus, Donna Dorr, Robert Brodsky, Gus Khursigara, Russell P. Rother, And Peter Hillmen , "Modification of the Eculizumab Dose to Successfully Manage Intravascular Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.", Blood, (20080101), pages 1 - 4, Blood, (20180117), XP055441621
OPPOSITION- Würzner Reinhard, Zimmerhackl Lothar B., "Therapeutic strategies for atypical and recurrent hemolytic uremic syndromes (HUS)", Complement and Kidney Disease, Basel, Birkhäuser-Verlag, (20060101), pages 149 - 163, doi:10.1007/3-7643-7428-4_9, ISBN 978-3-7643-7166-1, XP093138239
OPPOSITION- Chantal Loirat ; Marina Noris ; Véronique Fremeaux-Bacchi, "Complement and the atypical hemolytic uremic syndrome in children", Pediatric Nephrology ; Journal of the International Pediatric Nephrology Association, Springer, Berlin, DE, Berlin, DE , (20080702), vol. 23, no. 11, doi:10.1007/s00467-008-0872-4, ISSN 1432-198X, pages 1957 - 1972, XP019658955
OPPOSITION- Loirat Chantal; Noris Marina; Fremeaux-Bacchi Véronique, "Complement and the atypical hemolytic uremic syndrome in children", PEDIATRIC NEPHROLOGY., SPRINGER VERLAG, BERLIN., DE, DE , (20081101), vol. 23, no. 11, doi:10.1007/s00467-008-0872-4, ISSN 0931-041X, pages 1957 - 1972, XP037233611
OPPOSITION- De Sudarsana; Waters Aoife M.; Segal Audrey O.; Trautmann Agnes; Harvey Elizabeth A.; Licht Christoph, "Severe atypical HUS caused by CFH S1191L—case presentation and review of treatment options", PEDIATRIC NEPHROLOGY., SPRINGER VERLAG, BERLIN., DE, DE , (20100101), vol. 25, no. 1, doi:10.1007/s00467-009-1306-7, ISSN 0931-041X, pages 97 - 104, XP036959221
OPPOSITION- de Jorge, E.G. ; Paixao-Cavalcante, D. ; Rose, K.L. ; Cook, H.T. ; Botto, M. ; Pickering, M.C., "C5 activation is required for the development of atypical haemolytic uraemic syndrome in Cfh-/-.FH@D16-20 mice", Molecular Immunology, PERGAMON, GB, GB , (20081001), vol. 45, no. 16, doi:10.1016/j.molimm.2008.08.017, ISSN 0161-5890, pages 4100 - 4101, XP025896188
OPPOSITION- RICKLIN DANIEL, LAMBRIS J D, "Complement-targeted therapeutics.", Nature Biotechnology, Nature Publishing Group US, New York, New York, (20071101), vol. 25, no. 11, doi:10.1038/NBT1342, ISSN 1087-0156, pages 1265 - 1275, XP002546813
OPPOSITION- Rother R P ET AL, "Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria", Nature Biotechnology, Nature Publishing Group US, New York, New York, (20071212), vol. 25, no. 11, doi:10.1038/nbt1344, ISSN 1087-0156, pages 1256 - 1264, XP002553743
OPPOSITION- Marina Noris, Federica Mescia, Giuseppe Remuzzi, "STEC-HUS, atypical HUS and TTP are all diseases of complement activation", Nature reviews. Nephrology, Nature Publishing Group, GB, GB , vol. 8, no. 11, doi:10.1038/nrneph.2012.195, ISSN 1759-5061, pages 622 - 633, XP055259427
OPPOSITION- Davin Jean-Claude, Gracchi Valentina, Bouts Antonia, Groothoff Jaap, Strain Lisa, Goodship Tim, "Maintenance of Kidney Function Following Treatment With Eculizumab and Discontinuation of Plasma Exchange After a Third Kidney Transplant for Atypical Hemolytic Uremic Syndrome Associated With a CFH Mutation", American Journal of Kidney Diseases, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20091026), vol. 55, no. 4, doi:10.1053/j.ajkd.2009.08.011, ISSN 0272-6386, pages 708 - 711, XP093138989
OPPOSITION- Prüfer Friederike, Scheiring Johanna, Sautter Sabine, Jensen Dorthe, Treichl Ruth, Würzner Reinhard, Zimmerhackl L., "Terminal Complement Complex (C5b-9) in Children with Recurrent Hemolytic Uremic Syndrome", SEMINARS IN THROMBOSIS AND HEMOSTASIS, Thieme Medical Publishers, Inc., US, US , (20060301), vol. 32, no. 2, doi:10.1055/s-2006-939768, ISSN 0094-6176, pages 121 - 127, XP093138319
OPPOSITION- Jens Nürnberger, Thomas Philipp, Oliver Witzke, Anabelle Opazo Saez, Udo Vester, Hideo Andreas Baba, Andreas Kribben, Lothar Bernd Zimmerhackl, Andreas R. Janecke, Mato Nagel, Michael Kirschfink, "Eculizumab for Atypical Hemolytic–Uremic Syndrome", New England Journal of Medicine, New England Journal of Medicine, (20090129), vol. 360, no. 5, doi:10.1056/NEJMc0808527, ISSN 00284793, pages 542 - 544, XP055045531
OPPOSITION- Nürnberger Jens, Philipp Thomas, Witzke Oliver, Saez Anabelle Opazo, Vester Udo, Baba Hideo Andreas, Kribben Andreas, Zimmerhackl Lothar Bernd, Janecke Andreas R., Nagel Mato, Kirschfink Michael, "Eculizumab for Atypical Hemolytic-Uremic Syndrome", The New England journal of medicine, Massachusetts Medical Society, US, US , (20090129), vol. 360, no. 5, doi:10.1056/NEJMc0808527, ISSN 0028-4793, pages 542 - 544, XP093139023
OPPOSITION- Ralph A. Gruppo, Russell P. Rother, "Eculizumab for Congenital Atypical Hemolytic–Uremic Syndrome", New England Journal of Medicine, New England Journal of Medicine, (20090129), vol. 360, no. 5, doi:10.1056/NEJMc0809959, ISSN 00284793, pages 544 - 546, XP055186116
OPPOSITION- HILLMEN P, ET AL., "EFFECT OF ECULIZUMAB ON HEMOLYSIS AND TRANSFUSION REQUIREMENTS IN PATIENTS WITH PAROXYSMAL NOCTRURNAL HEMAGLOBINURIA", New England Journal of Medicine, The - NEJM, Massachusetts Medical Society, US, US , (20040205), vol. 350, no. 06, doi:10.1056/NEJMoa031688, ISSN 1533-4406, pages 552 - 559, XP009057948
OPPOSITION- HILLMEN PETER ET AL, "The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.", New England Journal of Medicine, The - NEJM, Massachusetts Medical Society, US, US , (20060921), vol. 355, no. 12, doi:10.1056/NEJMoa061648, ISSN 1533-4406, pages 1233 - 1243, XP002482088
OPPOSITION- C.M. Legendre, C. Licht, P. Muus, L.A. Greenbaum, S. Babu, C. Bedrosian, C. Bingham, D.J. Cohen, Y. Delmas, K. Douglas, F. Eitner, T. Feldkamp, D. Fouque, R.R. Furman, O. Gaber, M. Herthelius, M. Hourmant, D. Karpman, Y. Lebranchu, C. Mariat, J. Menne, B. Moulin, J. Nürnberger, M. Ogawa, G. Remuzzi, T. Richard, R. Sberro-Soussan, B. Severino, N.S. Sheerin, A. Trivelli, L.B. Zimmerhackl, T. Goodship, C. Loirat, "Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome", The New England journal of medicine, Massachusetts Medical Society, US, US , (20130606), vol. 368, no. 23, doi:10.1056/NEJMoa1208981, ISSN 0028-4793, pages 2169 - 2181, XP055688015
OPPOSITION- M. C. Pickering, J. Warren, K. L. Rose, F. Carlucci, Y. Wang, M. J. Walport, H. T. Cook, M. Botto, "Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20060620), vol. 103, no. 25, doi:10.1073/pnas.0601094103, ISSN 00278424, pages 9649 - 9654, XP055186139
OPPOSITION- E. G. De Jorge, C. L. Harris, J. Esparza-Gordillo, L. Carreras, E. A. Arranz, C. A. Garrido, M. Lopez-Trascasa, P. Sanchez-Corral, B. P. Morgan, S. R. De Cordoba, "Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20070102), vol. 104, no. 1, doi:10.1073/pnas.0603420103, ISSN 00278424, pages 240 - 245, XP055162429
OPPOSITION- Richards Anna, Kemp Elizabeth J., Liszewski M. Kathryn, Goodship Judith A., Lampe Anne K., Decorte Ronny, Müslümanogğlu M. Hamza, Kavukcu Salih, Filler Guido, Pirson Yves, Wen Leana S., Atkinson John P., Goodship Timothy H. J., "Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20031028), vol. 100, no. 22, doi:10.1073/pnas.2135497100, ISSN 0027-8424, pages 12966 - 12971, XP093138252
OPPOSITION- Matthew C. Pickering, Elena Goicoechea De Jorge, Rubén Martinez-Barricarte, Sergio Recalde, Alfredo Garcia-Layana, Kirsten L. Rose, Jill Moss, Mark J. Walport, H. Terence Cook, Santiago Rodriguez De Córdoba, Marina Botto, "Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains", Journal of Experimental Medicine, Rockefeller University Press, US, US , (20070611), vol. 204, no. 6, doi:10.1084/jem.20070301, ISSN 0022-1007, pages 1249 - 1256, XP055555092
OPPOSITION- PEREZ-CABALLERO D, ET AL, "Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome", The American Journal of Human Genetics, American society of human genetics , Chicago , IL, US, US , (20010101), vol. 68, no. 2, doi:10.1086/318201, ISSN 0002-9297, pages 478 - 484, XP002544684
OPPOSITION- Kavanagh D., Goodship T. H. J., Richards A., "Atypical haemolytic uraemic syndrome", BRITISH MEDICAL BULLETIN., CHURCHILL LIVINGSTONE, LONDON., GB, GB , (20060911), vol. 77-78, no. 1, doi:10.1093/bmb/ldl004, ISSN 0007-1420, pages 5 - 22, XP093138270
OPPOSITION- C. Mark Taylor; Sam Machin; Stephen J. Wigmore; Tim H. J. Goodship, "Clinical Practice Guidelines for the management of atypical Haemolytic Uraemic Syndrome in the United Kingdom", British Journal of Haematology, John Wiley, Hoboken, USA, Hoboken, USA, (20091011), vol. 148, no. 1, doi:10.1111/j.1365-2141.2009.07916.x, ISSN 0007-1048, pages 37 - 47, XP071161498
OPPOSITION- M. Noris; G. Remuzzi, "Translational Mini‐Review Series on Complement Factor H: Therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis", Clinical and experimental immunology, Wiley-Blackwell Publishing Ltd., GB, GB , (20071207), vol. 151, no. 2, doi:10.1111/j.1365-2249.2007.03558.x, ISSN 0009-9104, pages 199 - 209, XP071085769
OPPOSITION- Warwicker Paul, Goodship Timothy H.J., Donne Rosemary L., Pirson Yves, Nicholls Anthony, Ward Roy M., Turnpenny Peter, Goodship Judith A., "Genetic studies into inherited and sporadic hemolytic uremic syndrome", KIDNEY INTERNATIONAL, Nature Publishing Group, LONDON, GB, GB , (19980401), vol. 53, no. 4, doi:10.1111/j.1523-1755.1998.00824.x, ISSN 0085-2538, pages 836 - 844, XP093138251
OPPOSITION- Holers V M, "The spectrum of complement alternative pathway-mediated diseases", Immunological Reviews, Wiley-Blackwell Publishing, Inc., US, US , (20080601), vol. 223, no. 1, doi:10.1111/j.1600-065X.2008.00641.x, ISSN 0105-2896, pages 300 - 316, XP002553744
OPPOSITION- V. Chatelet; V. Frémeaux‐Bacchi; T. Lobbedez; M. Ficheux; B. Hurault de Ligny, "Safety and Long‐Term Efficacy of Eculizumab in a Renal Transplant Patient with Recurrent Atypical Hemolytic-Uremic Syndrome", American journal of transplantation, BLACKWELL MUNKSGAARD, DK, DK , (20090922), vol. 9, no. 11, doi:10.1111/j.1600-6143.2009.02817.x, ISSN 1600-6135, pages 2644 - 2645, XP072336075
OPPOSITION- Fremeaux-Bacchi V, "Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome", Journal of Medical Genetics, BMJ PUBLISHING GROUP, LONDON, GB, GB , (20040601), vol. 41, no. 6, doi:10.1136/jmg.2004.019083, ISSN 0022-2593, pages e84 - e84, XP093138254
OPPOSITION- David Kavanagh, Anna Richards, John Atkinson, "Complement Regulatory Genes and Hemolytic Uremic Syndromes", Annual Review of Medicine, Annual Reviews, (20080201), vol. 59, no. 1, doi:10.1146/annurev.med.59.060106.185110, ISSN 00664219, pages 293 - 309, XP055186059
OPPOSITION- David Kavanagh, Anna Richards, John Atkinson, "Complement Regulatory Genes and Hemolytic Uremic Syndromes", Annual Review of Medicine, Annual Reviews, (20080201), vol. 59, no. 1, doi:10.1146/annurev.med.59.060106.185110, ISSN 00664219, pages 293 - 309, XP055186136
OPPOSITION- HILL ANITA ET AL, "Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria", Blood, American Society of Hematology, US, US , (20051001), vol. 106, no. 7, doi:10.1182/blood-2005-02-0564, ISSN 0006-4971, pages 2559 - 2565, XP002482089
OPPOSITION- Socié Gerard; Hillmen Peter; Muus Petra; Schubert Jörg; Dührsen Ulrich; Risitano Antonio M.; Rother Russell P.; Brodsky Robert A.; Szer Jeffrey, "Sustained Improvements in Transfusion Requirements, Fatigue and Thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal Hemoglobinuria.", Blood, American Society of Hematology, US, US , (20071116), vol. 110, no. 11, doi:10.1182/blood.V110.11.3672.3672, ISSN 0006-4971, page 3672, XP086642549
OPPOSITION- Nuernberger Jens; Witzke Oliver; Rother Russell P.; Philipp Thomas; Vester Udo; Baba Hideo; Zimmerhackl Lothar Bernd; Kribben Andreas, "Successful Treatment of Atypical Hemolytic Uremic Syndrome with the Complement Inhibitor Eculizumab.", Blood, American Society of Hematology, US, US , (20081116), vol. 112, no. 11, doi:10.1182/blood.V112.11.2294.2294, ISSN 0006-4971, page 2294, XP086681033
OPPOSITION- Chatelet Valerie; Fremeaux-Bacchi Veronique; Ficheux Maxence; Lobbedez Thierry; Hurault-Deligny Bruno, "Efficacy of Eculizumab in a Plasmatherapy-Dependent Patient with Atypical Hemolytic Uremic Syndrome with C3 Mutation Following Plasmatherapy Withdrawal", Blood, American Society of Hematology, US, US , (20081116), vol. 112, no. 11, doi:10.1182/blood.V112.11.4579.4579, ISSN 0006-4971, page 4579, XP086679334
OPPOSITION- Takahiko Horiuchi, Tsukamoto Hiroshi, "Complement-targeted therapy: development of C5- and C5a-targeted inhibition", Inflammation and Regeneration, (20161201), vol. 36, no. 1, doi:10.1186/s41232-016-0013-6, pages 1 - 5, XP055644542
OPPOSITION- Dragon-Durey Marie-Agne[combining Grave Accent]s, Loirat Chantal, Cloarec Sylvie, Macher Marie-Alice, Blouin Jacques, Nivet Hubert, Weiss Laurence, Fridman Wolf Herman, Frémeaux-Bacchi Véronique, "Anti-Factor H Autoantibodies Associated with Atypical Hemolytic Uremic Syndrome", Journal of the American Society of Nephrology, WILLIAMS AND WILKINS, BALTIMORE, MD., US, US , (20050201), vol. 16, no. 2, doi:10.1681/ASN.2004050380, ISSN 1046-6673, pages 555 - 563, XP093138259
OPPOSITION- M. Noris, "Hemolytic Uremic Syndrome", Journal of the American Society of Nephrology, WILLIAMS AND WILKINS, BALTIMORE, MD., US, US , (2005), vol. 16, no. 4, doi:10.1681/ASN.2004100861, ISSN 1046-6673, pages 1035 - 1050, XP055439960
OPPOSITION- Schieppati A, Ruggenenti P, Cornejo R P, Ferrario F, Gregorini G, Zucchelli P, Rossi E, Remuzzi G, "Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome.", Journal of the American Society of Nephrology, WILLIAMS AND WILKINS, BALTIMORE, MD., US, US , (19920501), vol. 2, no. 11, doi:10.1681/ASN.V2111640, ISSN 1046-6673, pages 1640 - 1644, XP093138250
OPPOSITION- Raina Rupesh, Mangat Guneive, Hong Gordon, Shah Raghav, Nair Nikhil, Abboud Brian, Bagga Sumedha, Sethi Sidharth Kumar, "Anti-factor H antibody and its role in atypical hemolytic uremic syndrome", Frontiers in Immunology, Frontiers Media, Lausanne, CH, Lausanne, CH , (20220823), vol. 13, doi:10.3389/fimmu.2022.931210, ISSN 1664-3224, page 931210, XP093138266
SEARCH- REINHARD W�RZNER AND LOTHAR ZIMMERHACKL, Therapeutic strategies for atypical and recurrent hemolytic uremic syndromes (HUS), COMPLEMENT AND KIDNEY DISEASE,, PAGE(S) 149 - 163, (20060101), XP009161632 [Y] 1-18 * page 159, paragraph 3 - page 160, paragraph 1 *
SEARCH- CHANTAL LOIRAT ET AL, "Complement and the atypical hemolytic uremic syndrome in children", PEDIATRIC NEPHROLOGY ; JOURNAL OF THE INTERNATIONAL PEDIATRIC NEPHROLOGY ASSOCIATION, SPRINGER, BERLIN, DE, (20080702), vol. 23, no. 11, doi:10.1007/S00467-008-0872-4, ISSN 1432-198X, pages 1957 - 1972, XP019658955 [Y] 1-18 * page 10, column left, paragraph 4 - column right, paragraph 1 *
SEARCH- JENS N�RNBERGER ET AL, "Eculizumab for Atypical Hemolytic-Uremic Syndrome", NEW ENGLAND JOURNAL OF MEDICINE, (20090129), vol. 360, no. 5, doi:10.1056/NEJMc0808527, ISSN 0028-4793, pages 542 - 544, XP055045531 [PA] 7-18 * figure 1 *
SEARCH- RALPH A. GRUPPO ET AL, "Eculizumab for Congenital Atypical Hemolytic-Uremic Syndrome", NEW ENGLAND JOURNAL OF MEDICINE, (20090129), vol. 360, no. 5, doi:10.1056/NEJMc0809959, ISSN 0028-4793, pages 544 - 546, XP055186116 [PY] 1-18 * page 545, column right, paragraph 1 - page 546, column left, paragraph 1 *
SEARCH- "More on Eculizumab for Congenital Atypical Hemolytic-Uremic Syndrome", NEW ENGLAND JOURNAL OF MEDICINE, (20090514), vol. 360, no. 20, doi:10.1056/NEJMc090453, ISSN 0028-4793, pages 2142 - 2143, XP055186122 [PY] 1-18 * page 2142, column left, paragraph 2 - page 2143, column right, paragraph 1 *
SEARCH- HILLMEN P ET AL, "EFFECT OF ECULIZUMAB ON HEMOLYSIS AND TRANSFUSION REQUIREMENTS IN PATIENTS WITH PAROXYSMAL NOCTRURNAL HEMAGLOBINURIA", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, (20040205), vol. 350, no. 6, doi:10.1056/NEJMOA031688, ISSN 1533-4406, pages 552 - 559, XP009057948 [A] 1-18 * the whole document *
SEARCH- HILLMEN PETER ET AL, "The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, (20060921), vol. 355, no. 12, doi:10.1056/NEJMOA061648, ISSN 1533-4406, pages 1233 - 1243, XP002482088 [A] 1-18 * the whole document *
SEARCH- CHATELET V ET AL, "Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome.", AMERICAN JOURNAL OF TRANSPLANTATION : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF TRANSPLANTATION AND THE AMERICAN SOCIETY OF TRANSPLANT SURGEONS NOV 2009, (200911), vol. 9, no. 11, ISSN 1600-6143, pages 2644 - 2645, XP002739219 [PX] 1,7-9,17-18 * page 2644, column left, paragraph 1 - column right, paragraph 2; figure 1 * [Y] 1-18
SEARCH- DAVID KAVANAGH ET AL, "Complement Regulatory Genes and Hemolytic Uremic Syndromes", ANNUAL REVIEW OF MEDICINE, (20080201), vol. 59, no. 1, doi:10.1146/annurev.med.59.060106.185110, ISSN 0066-4219, pages 293 - 309, XP055186136 [Y] 1-18 * page 304, column right, paragraph 1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents